Emergent BioSolutions Inc

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

06 Apr 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19

02 Apr 2020 16:05:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

31 Mar 2020 16:05:10 By Nasdaq GlobeNewswire

EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

18 Mar 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

11 Mar 2020 16:21:56 By Nasdaq GlobeNewswire

Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

10 Mar 2020 05:30:10 By Nasdaq GlobeNewswire

NetDania - New 12 months High: Emergent BioSolutions Inc

21 Feb 2020 09:56:23 By NetDania Notify

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019

20 Feb 2020 16:31:41 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

03 Feb 2020 16:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency

31 Jan 2020 09:26:54 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate

13 Jan 2020 06:40:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast

13 Jan 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

06 Jan 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

20 Dec 2019 13:00:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

22 Nov 2019 08:19:21 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

21 Nov 2019 16:05:09 By Nasdaq GlobeNewswire

Emergent BioSolutions to Host 2019 Analyst and Investor Day

18 Nov 2019 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

06 Nov 2019 16:05:05 By Nasdaq GlobeNewswire

Emergent BioSolutions to Host 2019 Analyst & Investor Day

21 Oct 2019 06:30:09 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

10 Oct 2019 06:38:00 By Nasdaq GlobeNewswire